Read in the 10-K filed Feb 25, 2026We have engaged a third-party firm to assist the Company with the development and deployment of an AI tool, ADMAlytics, to improve efficiencies across our supply chain, production, and commercial operations. This tool has been used to assist with activities including plasma pool composition and identifying other manufacturing efficiencies to streamline certain operational processes. While we have successfully implemented ADMAlytics in certain aspects of our commercial manufacturing and expanded its use throughout fiscal year 2025, the development, implementation, and ongoing use of AI technologies involve inherent risks. While ADMA has not experienced any issues to date, these risks include potential data inaccuracies, flawed assumptions, system errors, cybersecurity vulnerabilities, unintended outcomes, and difficulties in integrating AI-driven insights into complex and highly regulated manufacturing and operational environments. If ADMAlytics fails to perform as intended or produces unreliable or biased outputs, our reputation could be harmed and we could be subject to legal exposure, which could adversely affect our business, results of operations, and financial condition.
Supply chain
451 of 1505 companies added a paragraph in Risk Factors that uses one of these words:
supply chain, supply chains, single source, sole source, shortage, shortages.
The paragraph is in the latest 10-K and nothing like it was in the one before.
It counts text; it does not say how serious a risk is. Words in capitals only (such as AI) must be in capitals.
By sector
Sector is the SEC's industry description of the company. The bar is the share of that sector's companies compared; each count opens that sector's quotes below.
- Computer Storage Devices 5 of 5
- Computer Communications Equipment 3 of 3
- Wholesale-Groceries & Related Products 3 of 3
- Apparel & Other Finishd Prods of Fabrics & Similar Matl 2 of 2
- Construction - Special Trade Contractors 2 of 2
- Miscellaneous Manufacturing Industries 2 of 2
- Ophthalmic Goods 2 of 2
- Optical Instruments & Lenses 2 of 2
- Paper Mills 2 of 2
- Wholesale-Computers & Peripheral Equipment & Software 2 of 2
- Abrasive, Asbestos & Misc Nonmetallic Mineral Prods 1 of 1
- Agricultural Production-Crops 1 of 1
- Canned, Fruits, Veg, Preserves, Jams & Jellies 1 of 1
- Carpets & Rugs 1 of 1
- Dolls & Stuffed Toys 1 of 1
- Fabricated Plate Work (Boiler Shops) 1 of 1
- Fabricated Structural Metal Products 1 of 1
- Flat Glass 1 of 1
- Lawn & Garden Tractors & Home Lawn & Gardens Equip 1 of 1
- Malt Beverages 1 of 1
- Meat Packing Plants 1 of 1
- Metal Doors, Sash, Frames, Moldings & Trim 1 of 1
- Miscellaneous Metal Ores 1 of 1
- Miscellaneous Transportation Equipment 1 of 1
- Motor Homes 1 of 1
- Oil Royalty Traders 1 of 1
- Ordnance & Accessories, (No Vehicles/Guided Missiles) 1 of 1
- Radiotelephone Communications 1 of 1
- Real Estate Operators (No Developers) & Lessors 1 of 1
- Retail-Jewelry Stores 1 of 1
- Retail-Radio, Tv & Consumer Electronics Stores 1 of 1
- Retail-Shoe Stores 1 of 1
- Savings Institutions, Not Federally Chartered 1 of 1
- Sawmills & Planting Mills, General 1 of 1
- Secondary Smelting & Refining of Nonferrous Metals 1 of 1
- Services-Motion Picture & Video Tape Production 1 of 1
- Services-Offices & Clinics of Doctors of Medicine 1 of 1
- Wholesale-Electrical Apparatus & Equipment, Wiring Supplies 1 of 1
- Wholesale-Hardware 1 of 1
- Wholesale-Motor Vehicle Supplies & New Parts 1 of 1
- Semiconductors & Related Devices 30 of 37
- Grain Mill Products 3 of 4
- Ship & Boat Building & Repairing 3 of 4
- Trucking (No Local) 5 of 7
- Biological Products, (No Diagnostic Substances) 16 of 23
- Calculating & Accounting Machines (No Electronic Computers) 2 of 3
- Canned, Frozen & Preservd Fruit, Veg & Food Specialties 2 of 3
- Computer & office Equipment 2 of 3
- Computer Peripheral Equipment, NEC 2 of 3
- Cutlery, Handtools & General Hardware 2 of 3
- Electronic Computers 2 of 3
- Engines & Turbines 2 of 3
- Guided Missiles & Space Vehicles & Parts 2 of 3
- Natural Gas Transmisison & Distribution 2 of 3
- Sporting & Athletic Goods, NEC 2 of 3
- Telephone Communications (No Radiotelephone) 2 of 3
- Wholesale-Drugs, Proprietaries & Druggists' Sundries 2 of 3
- Pharmaceutical Preparations 28 of 49
- Laboratory Analytical Instruments 4 of 7
- Orthopedic, Prosthetic & Surgical Appliances & Supplies 4 of 7
- Motor Vehicles & Passenger Car Bodies 4 of 8
- Chemicals & Allied Products 3 of 6
- Communications Services, NEC 3 of 6
- Retail-Family Clothing Stores 3 of 6
- Aircraft 2 of 4
- Cable & Other Pay Television Services 2 of 4
- Electromedical & Electrotherapeutic Apparatus 2 of 4
- Electronic Components & Accessories 2 of 4
- Real Estate Agents & Managers (For Others) 2 of 4
- Services-Commercial Physical & Biological Research 2 of 4
- Special Industry Machinery (No Metalworking Machinery) 2 of 4
- Cigarettes 1 of 2
- Communications Equipment, NEC 1 of 2
- Construction Machinery & Equip 1 of 2
- Dental Equipment & Supplies 1 of 2
- Drawing & Insulating of Nonferrous Wire 1 of 2
- Gas & Other Services Combined 1 of 2
- Household Appliances 1 of 2
- Leather & Leather Products 1 of 2
- Patent Owners & Lessors 1 of 2
- Retail-Department Stores 1 of 2
- Retail-Miscellaneous Shopping Goods Stores 1 of 2
- Retail-Retail Stores, NEC 1 of 2
- Services-Specialty Outpatient Facilities, NEC 1 of 2
- Special Industry Machinery, NEC 1 of 2
- Telephone & Telegraph Apparatus 1 of 2
- Wholesale-Chemicals & Allied Products 1 of 2
- Wholesale-Lumber & Other Construction Materials 1 of 2
- Motor Vehicle Parts & Accessories 7 of 15
- Surgical & Medical Instruments & Apparatus 10 of 22
- Services-Computer Integrated Systems Design 6 of 14
- Services-Medical Laboratories 3 of 7
- Food and Kindred Products 2 of 5
- Industrial Organic Chemicals 2 of 5
- Men's & Boys' Furnishgs, Work Clothg, & Allied Garments 2 of 5
- Mining & Quarrying of Nonmetallic Minerals (No Fuels) 2 of 5
- Miscellaneous Fabricated Metal Products 2 of 5
- Oil & Gas Field Services, NEC 2 of 5
- Perfumes, Cosmetics & Other Toilet Preparations 2 of 5
- Finance Services 13 of 34
- Real Estate Investment Trusts 30 of 84
- Operative Builders 3 of 9
- Retail-Variety Stores 3 of 9
- Air Transportation, Scheduled 2 of 6
- Heavy Construction Other Than Bldg Const - Contractors 2 of 6
- Metal Mining 2 of 6
- Oil & Gas Field Machinery & Equipment 2 of 6
- Printed Circuit Boards 2 of 6
- Search, Detection, Navigation, Guidance, Aeronautical Sys 2 of 6
- Arrangement of Transportation of Freight & Cargo 1 of 3
- Bottled & Canned Soft Drinks & Carbonated Waters 1 of 3
- Electronic Components, NEC 1 of 3
- Farm Machinery & Equipment 1 of 3
- Fats & Oils 1 of 3
- General Industrial Machinery & Equipment, NEC 1 of 3
- In Vitro & In Vivo Diagnostic Substances 1 of 3
- Miscellaneous Chemical Products 1 of 3
- Motors & Generators 1 of 3
- Refrigeration & Service Industry Machinery 1 of 3
- Retail-Auto & Home Supply Stores 1 of 3
- Retail-Building Materials, Hardware, Garden Supply 1 of 3
- Retail-Grocery Stores 1 of 3
- Rubber & Plastics Footwear 1 of 3
- Services-Engineering Services 1 of 3
- Soap, Detergents, Cleang Preparations, Perfumes, Cosmetics 1 of 3
- Television Broadcasting Stations 1 of 3
- Electric Services 8 of 26
- Other 3 of 10
- Commodity Contracts Brokers & Dealers 5 of 17
- Beverages 2 of 7
- Petroleum Refining 2 of 7
- Plastic Materials, Synth Resins & Nonvulcan Elastomers 2 of 7
- Water Transportation 2 of 7
- Industrial Instruments For Measurement, Display, and Control 2 of 8
- Aircraft Engines & Engine Parts 1 of 4
- Electronic & Other Electrical Equipment (No Computer Equip) 1 of 4
- Misc Industrial & Commercial Machinery & Equipment 1 of 4
- Plastics Products, NEC 1 of 4
- Pumps & Pumping Equipment 1 of 4
- Radio & Tv Broadcasting & Communications Equipment 1 of 4
- Retail-Eating & Drinking Places 1 of 4
- Retail-Lumber & Other Building Materials Dealers 1 of 4
- Services-Consumer Credit Reporting, Collection Agencies 1 of 4
- Services-General Medical & Surgical Hospitals, NEC 1 of 4
- Services-Home Health Care Services 1 of 4
- Water, Sewer, Pipeline, Comm & Power Line Construction 1 of 4
- Services-Prepackaged Software 19 of 81
- Retail-Eating Places 3 of 13
- Services-Computer Programming, Data Processing, Etc. 4 of 18
- Electric & Other Services Combined 3 of 14
- Security Brokers, Dealers & Flotation Companies 3 of 14
- National Commercial Banks 8 of 38
- Natural Gas Distribution 2 of 10
- Drilling Oil & Gas Wells 1 of 5
- Measuring & Controlling Devices, NEC 1 of 5
- Refuse Systems 1 of 5
- Investment Advice 5 of 26
- Fire, Marine & Casualty Insurance 5 of 30
- Miscellaneous Electrical Machinery, Equipment & Supplies 1 of 6
- Real Estate 1 of 6
- Retail-Catalog & Mail-Order Houses 1 of 6
- Retail-Auto Dealers & Gasoline Stations 2 of 13
- Personal Credit Institutions 1 of 7
- Transportation Services 1 of 7
- Crude Petroleum & Natural Gas 3 of 23
- Hospital & Medical Service Plans 1 of 8
- Security & Commodity Brokers, Dealers, Exchanges & Services 1 of 8
- State Commercial Banks 5 of 43
- Services-Business Services, NEC 4 of 37
- Natural Gas Transmission 1 of 10
- Insurance Agents, Brokers & Service 1 of 12
- Services-Computer Processing & Data Preparation 1 of 14
826 paragraphs · Biological Products, (No Diagnostic Substances) show all sectors
Read in the 10-K filed Feb 13, 2026We are expanding our manufacturing capabilities to support current and anticipated demand for our products and product candidates. These expansion efforts are complex, capital-intensive and subject to significant risks, including construction, validation and quality assurance challenges; delays or unfavorable outcomes from regulatory inspections or approvals; labor availability and workforce readiness issues; supply chain disruptions; and contractual disputes with suppliers or contractors. We may be unable to realize anticipated efficiencies or returns on our investments if there are delays or failures of our product development programs or our receipt of regulatory approvals, if our new or expanded facilities require extended periods to achieve planned production capacity or expected yields, or if demand for our products or product candidates changes or fails to materialize. These efforts often rely on a single or limited number of vendors and suppliers, and identifying or qualifying alternatives may not be feasible or may require significant time and expense due to the specialized nature of our manufacturing requirements. In addition, tariffs on imported equipment, construction materials or key inputs have increased our costs to a limited extent in 2025, and, going forward, such tariffs, or other tariffs imposed in the future, could further increase costs, potentially disrupt supply chains, and put at risk the timely and cost-effective execution of these projects.
Read in the 10-K filed Feb 13, 2026our product sales, business and results of operations. A significant worsening of global economic conditions could precipitate or materially amplify the other risks described herein. On April 2, 2025, the Administration issued an executive order (the April 2025 Tariff EO) imposing a universal 10% tariff on all imported goods, with certain exceptions including pharmaceuticals. The April 2025 Tariff EO imposed additional higher tariffs on approximately 60 countries with which the United States has trade deficits. Recent and ongoing changes in U.S. trade and tariff policies, including the imposition, modification, suspension and threatened expansion of tariffs on imported goods, as well as retaliatory measures by foreign governments, have increased uncertainty in the overall business and operating environment. Although certain pharmaceutical products are exempt from some tariffs, these measures have increased, and may continue to increase, our costs, including for materials, components and supplies used in research and development and manufacturing activities, have adversely affected, and may continue to adversely affect, our operations in various markets, and could disrupt global supply chains. On October 24, 2025, the Administration initiated, under the Trade Act of 1974, a Section 301 investigation of China’s implementation of the Economic and Trade Agreement between the U.S. and Chinese governments. This investigation, and any other 301 investigations initiated, may result in additional tariffs on imported goods from China and any other foreign markets subsequently investigated, respectively, potentially including pharmaceutical products and other goods that Amgen requires for the manufacture of our products. If subject to Section 301 tariffs, China, and other affected foreign governments, may retaliate against such tariffs by imposing tariffs of their own on U.S.-made goods. Given the many uncertainties and variables, it is currently unclear the extent, and degree, to which existing and future tariffs will disrupt and adversely affect our business activities (including product sales, and conduct of clinical trial and research and development activities), and the global economic environment, and/or amplify the other risks described herein.
Read in the 10-K filed Feb 24, 2026As a result of changes in tariffs that have been announced and/or implemented, and the underlying uncertainty currently surrounding international trade, we could experience a negative impact on our costs of materials and production processes, and supply chain disruptions and delays due to new or revised tariff policies or trade restrictions. If we are unable to obtain necessary raw materials or product components in sufficient quantities and in a timely manner due to disruptions in the global supply chain caused by macroeconomic events and conditions, the development, testing and clinical trials of our product candidates may be delayed or infeasible, and regulatory approval or commercial launch of any resulting product may be delayed or not obtained, which could significantly harm our business. We cannot yet predict the effect of the U.S. tariffs on imports, or the extent to which other countries will impose quotas, duties, tariffs, taxes or other similar restrictions upon imports or exports in the future, nor can we predict future trade policy or the terms of any renegotiated trade agreements and their impact on our business.
Read in the 10-K filed Feb 27, 2026Current or future tariffs will result in increased research and development expenses, including with respect to increased costs associated with APIs, raw materials, laboratory equipment and research materials and components. In addition, such tariffs will increase our supply chain complexity and could also potentially disrupt our existing supply chain. Trade restrictions affecting the import of materials necessary for clinical trials could result in delays to our development timelines. Increased development costs and extended development timelines could place us at a competitive disadvantage compared to companies operating in regions with more favorable trade relationships and could reduce investor confidence, negatively impacting our ability to secure additional financing on favorable terms or at all. In addition, as we advance toward commercialization in the future, tariffs and trade restrictions could hinder our ability to establish cost-effective production capabilities, negatively impacting our growth prospects.
Read in the 10-K filed Feb 12, 2026In addition, domestic and international political uncertainty, including implementation of aggressive trade policies, could impact our ability to conduct our clinical trials. For example, in early 2025, the United States imposed tariffs on imports on its trading partners, including Canada, Mexico, the EU and China. Historically, tariffs have led to increased trade and political tensions, between not only the U.S. and China, but also between the U.S. and other countries in the international community. In response to tariffs, other countries have implemented retaliatory tariffs on U.S. goods. Adverse reactions resulting from trade policies could reduce trade volume, investment, technological exchange and other economic activities between major international economies, resulting in a material adverse effect on global economic conditions and the stability of global financial markets. Additionally, in September 2025, the current administration also announced a 100% tariff on brand-name or patented drugs unless pharmaceutical companies expand their manufacturing operations in the U.S., and may impose more restrictions on goods. Although the pharmaceutical tariff is currently on hold, this could have a material adverse effect on our supply chain and business prospects as well as the larger biopharmaceutical industry. While certain tariffs have subsequently been suspended, modified or temporarily reduced, we cannot predict the results of trade negotiations or the outcome of ongoing legal challenges to tariff policies. Tariffs levied by the United States and other countries may lead to uncertainty in our ability to run clinical trials in preferred jurisdictions, impact our ability to import drug product, as well as raw materials to manufacture drug product domestically, and lead to uncertainty in our ability to supply drug product for our clinical trials, and otherwise increase the costs for us to run our business.
Read in the 10-K filed Feb 10, 2026The U.S. government has made and continues to make significant additional changes in U.S. trade policy and may continue to take future actions that could negatively impact U.S. trade. For example, the United States has announced tariffs on many goods imported from specified nations. In addition, there are currently discussions concerning potential increased tariffs for pharmaceutical products, which may impact our supply chain and create uncertainty in the broader pharmaceutical industry. While certain tariffs have been suspended, modified or temporarily reduced, we cannot predict the results of the U.S. government’s trade negotiations or the outcome of ongoing legal challenges to specific tariff policies. Changes in U.S. trade policy, including recently announced tariffs, related to countries where we or our suppliers operate could result in increased costs for raw materials, components, or finished goods for us, or challenges for our third-party contract manufacturers, distributors and suppliers to continue to meet demands for our products at current prices. These cost increases may reduce our margins, require us to raise prices, or make our products less competitive in the marketplace. Additionally, retaliatory tariffs imposed by other countries on U.S. exports could adversely impact demand for our products in international markets or increase the costs of conducting business. If we are unable to mitigate these risks through supply chain adjustments, pricing strategies, or other measures, our financial performance and growth prospects could be negatively affected.
Read in the 10-K filed Feb 24, 2026•U.S. Department of Commerce initiated an investigation on imports of pharmaceuticals and pharmaceutical ingredients, which may result in the current U.S. Presidential administration taking actions to impose potential tariffs or importation quotas in the pharmaceutical industry that could increase our manufacturing costs and adversely impact our supply chain resiliency and business competitiveness. For example, in September 2025, the U.S. Presidential administration announced plans to impose up to 100% tariffs on imported branded or patented pharmaceuticals, subject to certain exceptions. The specific impact remains uncertain at this time and is subject to the timing, scope and duration of any tariffs and actions imposed as well as broader tariffs and actions outside of the pharmaceutical industry.
Read in the 10-K filed Feb 24, 2026Our suppliers and third-party manufacturers and corporate partners similarly face these risks that could have an adverse effect on our business, and any disruption to their operations could have an adverse effect on our manufacturing and supply chain.
Read in the 10-K filed Feb 24, 2026We are undertaking significant multi‑year capital investments to expand our U.S. manufacturing capabilities and accelerate R&D, including our initiative to invest $32 billion in the U.S. through 2030. These investments are subject to numerous risks, including construction and commissioning delays, cost inflation, supply chain constraints, contractor performance, permitting and zoning challenges and the availability of skilled labor, and we may not complete our announced investments on a timely basis or at all. New or expanded facilities must meet cGMP and other regulatory requirements, are subject to FDA and other inspections, process validation and qualification, and their construction depends on third-party suppliers and partners whose performance we do not control. Any failure, delay, observation or remediation requirement could defer or limit production, increase costs or result in enforcement actions or other liabilities. We may not realize anticipated economic, employment, productivity, scale or innovation benefits, anticipated cost savings or future growth, and our reputation may be damaged, if these projects are delayed or unable to be completed in a cost-effective manner. This could also lead to underutilized assets, inventory write‑offs or asset impairments. Changes in laws or policies, including drug pricing reform, tax credits and incentives, environmental, health and safety standards, or tariff, trade and sourcing rules, could reduce expected returns on our investments or increase investment or operating costs. In addition, these initiatives require significant attention from management, capital expenditures and ongoing operating expenses and may increase variability in our margins and cash flows. Any of the foregoing could materially adversely affect our business, financial condition, results of operations, cash flows and reputation.
Read in the 10-K filed Feb 17, 2026Workforce reduction at federal agencies and changes in U.S. trade policy, including tariffs and potential countermeasures by trading partners, could delay regulatory approval and increase our or our partners’ costs, disrupt global supply chains and have a material adverse impact on our business, financial condition, and results of operations.
Read in the 10-K filed Feb 17, 2026The current federal government administration has increased, and has indicated a willingness to continue to increase, the use of tariffs by the U.S. to accomplish certain policy goals. Such tariffs and any countermeasures by the U.S.’ trading partners could increase the cost of raw materials, components and finished goods necessary for our or our partners’ operations, disrupt global supply chains, create additional operational challenges and cause widespread uncertainty in the financial markets. Further, it is possible the administration’s trade policy changes directly impacting the biopharmaceutical industry and related uncertainty about such policy changes could increase volatility in the market valuation of companies in the healthcare industry. Because of these dynamics, we cannot predict the impact of any future changes to international trading relationships or the ultimate impact recently adopted tariff policies will have on our business. Such changes in tariffs and trade regulations could have a material adverse effect on our financial condition, results of operations and cash flows. Additionally, recent widespread reductions in workforce at federal health agencies, including the FDA, could have a negative impact on the speed with which our products or devices and our partners’ products are reviewed and approved for commercialization.
Read in the 10-K filed Feb 26, 2026Further, there have been, and may continue to be, significant changes to U.S. trade policies, sanctions, legislation, treaties, and tariffs, including, but not limited to, trade policies and tariffs affecting products from outside of the U.S. The extent and duration of increased tariffs and the resulting impact on general economic conditions and on our business are not known and depend on various factors, such as negotiations between the U.S. and affected countries, their respective responses, potential exemptions or exclusions, and availability and cost of alternative sources of supply. Supply chain disruptions and delays could also negatively impact our cost of materials and production processes. If we are unable to obtain these materials in sufficient quantity and in a timely manner, the development, testing, and our clinical trials and any future product candidates may be delayed or infeasible, and regulatory approval or commercial launch may be delayed or not obtained, which could significantly harm our business.
Read in the 10-K filed Feb 11, 2026We operate in a global economy, and our business depends on a global supply chain for the development, manufacturing, and distribution of our products, and for the advancement of our development programs. There is inherent risk, based on the complex relationships among the U.S. and the countries in which we conduct our business, that political, diplomatic, and national security factors can lead to global trade restrictions and changes in trade policies and export regulations that may adversely affect our business and operations.
Read in the 10-K filed Feb 11, 2026We source and procure APIs, precursor chemicals, and specialized equipment from international suppliers, with substantial reliance on foreign contract manufacturers in Europe. Tariff policies, particularly those affecting pharmaceutical products, could increase our costs and reduce our profitability. Additionally, recent policy discussions have included potential targeted tariffs or other trade measures specifically aimed at pharmaceutical products and ingredients as part of broader healthcare cost control or national security initiatives. In April 2025, the U.S. Department of Commerce initiated an investigation on imports of pharmaceuticals and pharmaceutical ingredients, which may result in the current U.S. presidential administration taking actions to impose tariffs on the pharmaceutical industry. The U.S. presidential administration also indicated that it may impose a 100% tariff on any branded or patented pharmaceutical product, unless a company is building a pharmaceutical manufacturing plant in the U.S. The specific impact of the investigation and announcements to enact substantial tariffs on patented pharmaceutical products remain uncertain at this time but could negatively impact our business and operations. Unlike consumer goods, pharmaceuticals face unique regulatory constraints that make rapid supply chain adjustments particularly difficult and costly. Should tariffs be imposed specifically targeting pharmaceutical imports, our production costs could rise, and it would be difficult and costly to qualify alternative sources within another country with a lower tariff rate or within the U.S., as developing and qualifying alternative sources typically requires substantial time, investment, and regulatory approvals.
Read in the 10-K filed Feb 11, 2026It may be difficult and/or costly to detect, investigate, mitigate, contain, and remediate a security incident. Our efforts to do so may not be successful. Actions taken by us or the third parties with whom we work to detect, investigate, mitigate, contain, and remediate a security incident could result in outages, data losses, and disruptions of our business. Threat actors may also gain access to other networks and systems after a compromise of our networks and systems. For example, threat actors may use an initial compromise of one part of our environment to gain access to other parts of our environment, or leverage a compromise of our networks or systems to gain access to the networks or systems of third parties with whom we work, such as through phishing or supply chain attacks.
Read in the 10-K filed Feb 25, 2026We currently do business with companies in China, including some that have been referenced in earlier versions of the BIOSECURE Act and related policy discussions, and certain counterparties could be impacted by these legislative actions or regulatory lists. Changes in laws, regulations, or executive orders — or the issuance of lists identifying covered entities — could materially affect our collaborations, supply chains, research partnerships, manufacturing relationships, and access to certain services or technologies.
Read in the 10-K filed Mar 3, 2026Failure to maintain compliance with cGMP can result in regulatory action against our third-party manufacturers, including FDA sanctions, which could disrupt our manufacturing and supply chain and lead to delays in our clinical development programs, regulatory submissions or approvals, or commercial supply, if approved. In addition, delays in securing or maintaining manufacturing capacity for drug substance, fill-finish, labeling and packaging, or failures by our contract manufacturers or suppliers to perform as required, could delay clinical trials, regulatory filings, or commercial launches, which could negatively affect our business.
Read in the 10-K filed Mar 3, 2026U.S. and global markets have recently been experiencing volatility and disruption caused by economic uncertainty, including as a result of geopolitical instability, ongoing military conflicts, new regulatory activities and economic policies, and high inflation and interest rates. We are continuing to monitor global capital markets and assessing the potential impact of these factors on our business, including the impact on the supply chains we rely on for the manufacture of apitegromab, SRK-181, SRK-439, and any other current or future product candidates.
Read in the 10-K filed Mar 3, 2026Further, there have been, and may continue to be, significant changes to U.S. trade policies, sanctions, legislation, treaties and tariffs, including, but not limited to, trade policies and tariffs affecting products from outside of the U.S. The extent and duration of increased tariffs and the resulting impact on general economic conditions and on our business are uncertain and depend on various factors, such as negotiations between the U.S. and affected countries, the responses of other countries or regions, exemptions or exclusions that may be granted, availability and cost of alternative sources of supply, and demand in affected markets. While many of our supply chain and manufacturing activities occur within the U.S., we rely on globally sourced raw materials, components, and consumables. As a result, changes in trade policies, including the imposition of tariffs, export restrictions, or other geopolitical restrictions could result in increased costs or cause delays in the procurement of necessary materials or services. Any such disruptions in the global supply chain caused by macroeconomic events and conditions could adversely affect the development, testing and clinical trials of apitegromab, SRK-181, SRK-439, and any future product candidates, or it may be delayed or infeasible, and regulatory approval or commercial launch of any resulting product may be delayed or not obtained, which could significantly harm our business.
Read in the 10-K filed Feb 23, 2026Any unfavorable government policies on international trade, such as capital controls or tariffs, or any countermeasures imposed in response thereto, may negatively affect the demand and competitive position of our product or future products to the extent any of our product candidates are approved for commercial sale, negatively affect our costs, or negatively impact our supply chain, among other potential negative impacts. If any tariffs are reinstated, any new tariffs, legislation and/or regulations are implemented, or if existing trade agreements are renegotiated or, in particular, if the U.S.
Read in the 10-K filed Aug 24, 2026For instance, our use of animal-derived materials in certain products and manufacturing processes subjects us to regulatory, supply chain, quality, and reputational risks that could adversely affect our business. The sourcing, processing, importation, exportation, handling, storage, transportation and use of animal-derived materials are subject to complex and evolving laws, regulations and governmental oversight, including requirements administered by the USDA, APHIS, and the FDA, as well as customs authorities and comparable regulatory agencies in foreign jurisdictions. Changes in applicable regulations, guidance, interpretations, permitting requirements, certification standards or enforcement priorities could increase our compliance costs, restrict our ability to source or distribute affected products, delay shipments, interrupt manufacturing activities or adversely affect customer demand.
Read in the 10-K filed Nov 17, 2025The global economy has been impacted by geopolitical tensions. For example, new U.S. federal administration has recently imposed significant new tariffs on imports, which, along with other U.S. trade actions, have triggered retaliatory actions by certain affected countries. These geopolitical tensions could result in, among other things, macroeconomic uncertainty, cyberattacks, supply chain disruptions, higher costs and changes to foreign exchange rates and financial markets. In addition, tariffs and trade restrictions may result in increased production costs and product pricing, supply chain disruptions, limited access to markets and uncertainty related to planning long-term investments and strategies. Additionally, the administration's halt on certain federal research grants may negatively impact our industry. Any prolonged reductions in such funding could slow innovation, delay collaborations and limit the adoption of new technologies that contribute to our business growth. If these or similar policy changes continue or expand, we may face increased costs or impact on the demand for our products. We are monitoring and evaluating any potential impacts that global economic conditions and other policy changes may have on our business, and we are considering ways in which we may offset any impacts. However, there is no assurance that we will be successful in mitigating the effects in the current environment. Although we cannot predict the full extent of these impacts, any such policy changes could adversely affect our business, financial condition and results of operations.
Read in the 10-K filed Nov 17, 2025•trade and national security disputes, particularly with China, including the effect of sanctions, tariffs and other trade restrictions that may affect supply chain or sales opportunities in the United States, China and Europe;
Read in the 10-K filed Feb 26, 2026Furthermore, there have been and continue to be a number of initiatives at the federal and state levels that seek to reduce healthcare costs. In March 2010, President Obama signed into law the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act (jointly, the ACA), which includes measures to significantly change the way health care is financed by both governmental and private insurers. In August 2022, President Biden signed the Inflation Reduction Act (“IRA”), which permitted for the first time the Department of Health and Human Services (“HHS”) to negotiate prices directly with participating manufacturers for certain high expenditure, qualifying single source Medicare drugs without generic or biosimilar competition. In May 2025, President Trump signed an Executive Order intended to deliver MFN drug pricing to American patients. Follow-on efforts, including negotiating MFN agreements with pharmaceutical companies and proposing CMMI models with international benchmarks, seek to effectuate the order.